Prediction of response to dupilumab treatment
- 11 May 2023
- journal article
- editorial
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 188 (6) , e41
Abstract
One of the holy grails of modern medicine is choosing the right drug for the right patient. In this issue of the BJD, Wu et al. present their search for predictive serum biomarkers in patients with atopic dermatitis (AD) treated with dupilumab.1 Treatment options for moderate-to-severe AD have evolved since registration of the first biologic, dupilumab, in 2017. Currently, there are two biologics and three Janus kinase inhibitors registered for the treatment of moderate-to-severe AD. Although this new armamentarium fills a high unmet need, success in choosing the right drug for the right patient remains elusive. Currently, treatment decisions in patients eligible for advanced systemics are largely based on expert opinion and patient preferences, such as preferred route of administration (e.g. oral vs. subcutaneous). This often results in a trial-and-error approach and unnecessary exposure of patients to drugs that are not effective, and may result in side-effects. In addition, it leads to inefficient use of expensive drugs in an era of exponentially increasing healthcare expenses. Predictive biomarkers have the potential to optimize treatment response, minimize side-effects and ultimately reduce healthcare costs.Keywords
This publication has 5 references indexed in Scilit:
- Proteomic characterization of atopic dermatitis blood from infancy to adulthoodJournal of the American Academy of Dermatology, 2023
- Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumabBritish Journal of Dermatology, 2023
- Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkersJournal of Allergy and Clinical Immunology, 2021
- Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitisJournal of Allergy and Clinical Immunology, 2019
- Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysisJournal of Allergy and Clinical Immunology, 2017